Elyse Swallow

Education
M.P.P. and M.A., economics, Duke University; B.A., philosophy, Smith College
Summary of Experience
Ms. Swallow provides strategic expertise to life sciences companies and policymakers. She specializes in applying quantitative methods to real-world problems involving evaluation, decision making, strategy, and public policy in the health care and social policy sectors. She has more than 15 years of experience leading data analytics implementation, real-world evidence (RWE) generation, regulatory submissions, analytic platform design, and trial design. Ms. Swallow’s expertise includes regulatory-grade indirect treatment comparisons, survey research, database analyses, natural history studies, brand strategy, policy evaluation, RWE development, individualized medicine, and predictive analytics. Additionally, she has led health and social policy program evaluations. Ms. Swallow has worked across disease areas, including obesity, rare diseases, immunology, multiple sclerosis, hematology, oncology, and renal disease. Her work has been used to inform regulatory and reimbursement decisions in US and global markets, published in numerous peer-reviewed journals, and presented at dozens of clinical and economic research conferences.
-
Comparative effectiveness and safety of ozanimod versus other oral DMTs in relapsing-remitting multiple sclerosis: a synthesis of matching-adjusted indirect comparisons
Therapeutic Advances in Neurological Disorders, 2024
2024Paul D, Swallow E, Patterson-Lomba O, Branchcomb T, N'Dri L, Gomez-Lievano A, Liu J, Dua A, McGinley M
HEOR, Epidemiology & Market Access -
Trends in Prevalence and Incidence of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Among Adults and Children in a US Employer-Sponsored Insured Population
JAMA Dermatology, 2023
2023Mostaghimi A, Gao W, Ray M, Bartolome L, Wang T, Carley C, Done N, Swallow E
HEOR, Epidemiology & Market Access -
Association of Serum Calcium and Phosphate with Incident Cardiovascular Disease in Patients with Hypoparathyroidism
American Journal of Cardiology, 2023
2023Kaul S, Ayodele O, Chen K, Cook EE, Swallow E, Rejnmark L, Gosmanova EO
HEOR, Epidemiology & Market Access -
Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis in the United States
Neurology and Therapy, 2023
2023Kantor D, Pham T, Patterson-Lomba O, Swallow E, Dua A, Gupte-Singh K
HEOR, Epidemiology & Market Access -
Patient Characteristics Associated with All-Cause Healthcare Costs of Alopecia Areata in the United States
Journal of Medical Economics, 2023
2023Gao W, Mostaghimi A, Gandhi K, Done N, Ray M, Signorovitch J, Swallow E, Carley C, Wang T, Sikirica V
HEOR, Epidemiology & Market Access -
Real-World Outcomes Associated with Vonoprazan-Based Versus Proton Pump Inhibitor-Based Therapy for Helicobacter Pylori Infection in Japan
Therapeutic Advances in Gastroenterology, 2023
2023Howden CW, Cook EE, Swallow E, Yang K, Guo H, Pelletier C, Jacob R, Sugano K
HEOR, Epidemiology & Market Access -
Benefits of Autoantibody Enrichment in Early Rheumatoid arthritis: Analysis of Efficacy Outcomes in Four Pooled Abatacept Trials
Rheumatology and Therapy, 2023
2023Kaleb Michaud K, Conaghan PG, Park SH, Lozenski K, Fillbrunn M, Khaychuk V, Swallow E, Vaile J, Lane H, Nguyen H, Pope J
HEOR, Epidemiology & Market Access -
Burden of Illness and Treatment Patterns among Patients with Von Willebrand Disease in Us Clinical Practice
Clinical and Applied Thrombosis/Hemostasis, 2023
2023Swallow E, Marden JR, Billmyer E, Yim E, Sun SX
HEOR, Epidemiology & Market Access -
Comparative Efficacy and Safety of Ozanimod and Ponesimod for Relapsing Multiple Sclerosis: A Matching-Adjusted Indirect Comparison
Multiple Sclerosis and Related Disorders, 2023
2023Swallow E, Pham T, Patterson-Lomba O, Yin L, Gomez-Lievano A, Liu J, Tencer T, Gupte-Singh K
HEOR, Epidemiology & Market Access -
Avatrombopag treatment response in patients with immune thrombocytopenia: the REAL-AVA 1.0 study
Therapeutic Advances in Hematology, 2023
2023Oladapo A, Kolodny S, Vredenburg M, Swallow E, Goldschmidt D, Sarathy K, Lopez P, Maitland H, Yee J
HEOR, Epidemiology & Market Access -
Real-World Treatment Patterns among Patients with Alopecia Areata in the USA: A Retrospective Claims Analysis
Acta Dermato-Venereologica, 2023
2023Done N, Bartolome L, Swallow E, Gao W, Carley C, Wang T, Mostaghimi A
HEOR, Epidemiology & Market Access -
Direct health care costs associated with COVID-19 in the United States
Journal of Managed Care & Specialty Pharmacy, 2022
2022DeMartino J, Swallow E, Goldschmidt D, Yang K, Viola M, Radtke T, Kirson N
HEOR, Epidemiology & Market Access -
Five-Year Estimated Glomerular Filtration Rate in Adults with Chronic Hypoparathyroidism Treated with rhPTH(1-84): A Retrospective Cohort Study
Advances in Therapy, 2022
2022Ayodele O, Rejnmark L, Mu F, Lax A, Berman R, Swallow E, Gosmanova EO
HEOR, Epidemiology & Market Access -
The societal economic value of COVID-19 vaccines in the United States
Journal of Medical Economics, 2022
2022Kirson N, Swallow E, Lu J, Mesa-Frias M, Bookhart B, Maynard J, Shivdasani Y, Lefebvre P
HEOR, Epidemiology & Market Access -
Increasing COVID-19 vaccination in the United States: projected impact on cases, hospitalizations, and deaths by age and racial group
Public Health, 2022
2022Kirson N, Swallow E, Lu J, Foroughi C, Bookhart B, DeMartino JK, Maynard J, Shivdasani Y, Eid D, Lefebvre P
HEOR, Epidemiology & Market Access -
Healthcare Utilization and Costs Among US Adolescents With Alopecia Areata
Journal of Health Economics and Outcomes Research, 2022
2022Ray M, Swallow E, Gandhi K, Carley C, Sikirica V, Wang T, Done N, Signorovitch J, Mostaghimi A
HEOR, Epidemiology & Market Access -
The risk of chronic kidney disease development in adult patients with chronic hypoparathyroidism treated with rhPTH(1-84): A retrospective cohort study
Clinical Endocrinology, 2022
2022Rejnmark L, Ayodele O, Lax A, Mu F, Swallow E, Gosmanova EO
HEOR, Epidemiology & Market Access -
Lower Risk of Cardiovascular Events in Adult Patients with Chronic Hypoparathyroidism Treated with rhPTH(1-84): A Retrospective Cohort Study
Advances in Therapy, 2022
2022Ayodele O, Mu F, Berman R, Swallow E, Rejnmark L, Gosmanova EO, Kaul S
HEOR, Epidemiology & Market Access -
All-cause health care resource utilization and costs among adults with alopecia areata: A retrospective claims database study in the United States
Journal of Managed Care & Specialty Pharmacy, 2022
2022Mostaghimi A, Gandhi K, Done N, Ray M, Gao W, Carley C, Wang T, Swallow E, Sikirica V
HEOR, Epidemiology & Market Access -
Risk of Chronic Kidney Disease in Adult Patients With Chronic Hypoparathyroidism Treated With rhPTH(1-84) Compared With a Historical Control Cohort
European Congress of Endocrinology, 2021
2021Gosmanova EO, Ayodele O, Sherry N, Mu F, Briggs A, Swallow E, Rejnmark L
HEOR, Epidemiology & Market Access -
Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis
Multiple Sclerosis Journal – Experimental, Translational and Clinical, 2021
2021Healy BC, Glanz BI, Swallow E, Signorovitch J, Hagan K, Silva D, Pelletier C, Chitnis T, Weiner H
HEOR, Epidemiology & Market Access -
Real-world migraine-related healthcare resource utilization and costs associated with improved vs. worsened/stable migraine: a panel-based chart review in France, Germany, Italy, and Spain
Journal of Medical Economics, 2021
2021Vo P, Swallow E, Wu E, Zichlin ML, Katcher N, Maier-Peuschel M, Naclerio M, Ritrovato D, Joshi TSP, Ferraris M
HEOR, Epidemiology & Market Access -
Risk of Cardiovascular Conditions in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study
Advances in Therapy, 2021
2021Gosmanova EO, Chen K, Ketteler M, Rejnmark L, Mu F, Swallow E, Briggs A, Sherry N, Kaul S
HEOR, Epidemiology & Market Access -
Risk of Chronic Kidney Disease and Estimated Glomerular Filtration Rate Decline in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study
Advances in Therapy, 2021
2021Gosmanova EO, Chen K, Rejnmark L, Mu F, Swallow E, Briggs A, Ayodele O, Sherry N, Ketteler M
HEOR, Epidemiology & Market Access -
Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis
Journal of Comparative Effectiveness Research, 2020
2020Swallow E, Patterson-Lomba O, Yin L, Mehta R, Pelletier C, Kao D, Sheffield JK, Stonehouse T, Signorovitch J
HEOR, Epidemiology & Market Access -
Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma
Clinical Genitourinary Cancer, 2020
2020Cao X, Tang D, Ratto B, Poole A, Ravichandran S, Jin L, Gao W, Swallow E, Vogelzang NJ
HEOR, Epidemiology & Market Access -
Five-year Estimated Glomerular Filtration Rate in Patients With Hypoparathyroidism Treated With and Without rhPTH(1-84)
The Journal of Clinical Endocrinology and Metabolism, 2020
2020Chen KS, Gosmanova EO, Curhan GC, Ketteler M, Rubin M, Swallow E, Zhao J, Wang J, Sherry N, Krasner A, Bilezikian JP
HEOR, Epidemiology & Market Access -
Causal inference and adjustment for reference-arm risk in indirect treatment comparison meta-analysis
Journal of Comparative Effectiveness Research, 2020
2020Swallow E, Patterson-Lomba O, Ayyagari R, Pelletier C, Mehta R, Signorovitch J
HEOR, Epidemiology & Market Access -
Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States
Gynecologic Oncology, 2020
2020Muston D, Hettle R, Monberg M, McLaurin KK, Gao W, Swallow E, Zhang S, Kalemaj I, Signorovitch J, Moore K
HEOR, Epidemiology & Market Access -
A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer
Pharmacoeconomics, 2020
2020Gao W, Muston D, Monberg M, McLaurin K, Hettle R, Szamreta E, Swallow E, Zhang S, Kalemaj I, Signorovitch J, McQueen RB
HEOR, Epidemiology & Market Access -
Real-world healthcare resource utilization related to migraine treatment failure: a panel-based chart review in France, Germany, Italy, and Spain
Journal of Medical Economics, 2019
2019Vo P, Gao W, Zichlin ML, Fuqua E, Fadli E, Vazquez MA, Tarancón T, Mahieu N, Maier-Peuschel M, Rossi S, Naclerio M, Ritrovato D, Swallow E
HEOR, Epidemiology & Market Access -
Migraine-related healthcare resource use in the emergency department setting: a panel-based chart review in France, Germany, Italy, and Spain
Journal of Medical Economics, 2019
2019Vo P, Gao W, Zichlin ML, Fuqua E, Fadli E, Vazquez MA, Tarancón T, Mahieu N, Maier-Peuschel M, Rossi S, Naclerio M, Ritrovato D, Swallow E
HEOR, Epidemiology & Market Access -
The additional costs per month of progression-free survival and overall survival: An economic model comparing everolimus with cabozantinib, nivolumab, and axitinib for second-line treatment of metasta
Journal of Managed Care and Specialty Pharmacy. 01 Apr 2018;24(4):335-343c.
2018Swallow E, Messali A, Ghate S, McDonald E, Duchesneau E, Perez JR
-
Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data
Journal of Managed Care & Specialty Pharmacy, 2018 Jun;24(6):525-533
2018Vogelzang NJ, Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N
HEOR, Epidemiology & Market Access -
Epilepsy treatment patterns among patients with tuberous sclerosis complex
Journal of the Neurological Sciences. 2018 Aug 15;391:104-108
2018Song J, Swallow E, Said Q, Peeples M, Meiselbach M, Signorovitch J, Kohrman M, Korf B, Krueger D, Wong M, Sparagana S
HEOR, Epidemiology & Market Access -
Antiepileptic Drug Titration and Related Health Care Resource Use and Costs
Journal of Managed Care & Specialty Pharmacy. 2018 Sep;24(9):929-938
2018Fishman J, Kalilani L, Song Y, Swallow E, Wild I
HEOR, Epidemiology & Market Access -
Patterns of Disease Monitoring and Treatment Among Patients With Tuberous Sclerosis Complex-related Angiomyolipomas
Urology. Jun 2017;104:110-114
2017Swallow E, King S, Song J, Peeples M, Signorovitch JE, Liu Z, Prestifilippo J, Frost M, Kohrman M, Korf B, Krueger D, Sparagana S
HEOR, Epidemiology & Market Access -
Characteristics and outcomes of ALK+ non-small cell lung cancer patients in Korea
Asia-Pacific Journal of Clinical Oncology. Oct 2017;13(5):e239-e245
2017Lim SH, Yoh KA, Lee JS, Ahn MJ, Kim YJ, Kim SH, Zhang J, Patel D, Swallow E, Kageleiry A, Galebach P, Lee D, Stein K, Degun R, Park K
HEOR, Epidemiology & Market Access -
Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis
Clinical Genitourinary Cancer. Aug 2017;15(4):e573-e582
2017Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Perez JR, Agarwal N, Vogelzang NJ
HEOR, Epidemiology & Market Access -
Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam?
Cns Drugs. Oct 2017;31(10):899-910
2017Swallow E, Fang A, Signorovitch J, Plumb J, Borghs S
HEOR, Epidemiology & Market Access -
Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis
Advances in Therapy. Nov 2017;34(11):2452-2465
2017Vogelzang NJ, Pal SK, Ghate SR, Swallow E, Li N, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N
HEOR, Epidemiology & Market Access -
Patterns of Disease Monitoring and Treatment Among Patients with Tuberous Sclerosis Complex-related (1)
Urology. Jun 2017;104:110-114
2017Swallow E, King S, Song J, Peeples M, Signorovitch JE, Liu Z, Prestifilippo J, Frost M, Kohrman M, Korf B, Krueger D, Sparagana S
HEOR, Epidemiology & Market Access -
Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy
Neuromuscuarl Disorders, 2016 05. e-pub ahead of print 2016/07/18; doi: 10.1016/j.nmd.2016.05.016.
2016Mercuri E, Signorovitch J, Swallow E, Song J, Ward SJ.
HEOR, Epidemiology & Market Access -
Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison
Journal of Comparative Effectiveness Research, 2016 03; 5(2): 129-139. e-pub ahead of print 2015/09/22
2016Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Mu F, Kim S, Noviello S, Signorovitch J.
-
Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison
Clinical Therapeutics, 2016 02; 38(2): 404-412. e-pub ahead of print 2016/02/04
2016Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Peeples M, Mu F, Ackerman P, Signorovitch J.
-
Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular D(1)
PLOS ONE, 2016 Oct 13;11(10):e0164684
2016Goemans N, Vanden Hauwe M, Signorovitch J, Swallow E, Song J
-
Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies
PLoS One. 2014 Dec 10;9(12):e114264
2014Heng DY, Signorovitch J, Swallow E, Li N, Zhong Y, Qin P, Zhuo DY, Wang X, Park J, Stergiopoulos S, Kollmannsberger C
HEOR, Epidemiology & Market Access -
Real-world adherence and persistence associated with nebivolol or hydrochlorothiazide as add-on treatment for hypertension
Curr Med Res Opin. 2014 Apr;30(4):637-43
2014Chen S, Macaulay D, Swallow E, Diener M, Farooqui S, Xie J, Wu EQ
HEOR, Epidemiology & Market Access -
Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012
Curr Med Res Opin. 2014 Aug;30(8):1537-45
2014Swallow E, Zhang J, Thomason D, Tan RD, Kageleiry A, Signorovitch J
HEOR, Epidemiology & Market Access -
Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison
Exp Hematol Oncol. 2013 Dec 6;2(1):32
2013Signorovitch J, Swallow E, Kantor E, Wang X, Klimovsky J, Haas T, Devine B, Metrakos P
HEOR, Epidemiology & Market Access -
A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care
Pediatr Pulmonol. 2013 Oct;48(10):954-61
2012Sawicki GS, Ayyagari R, Zhang J, Signorovitch JE, Fan L, Swallow E, Latremouille-Viau D, Wu EQ, Shi L
HEOR, Epidemiology & Market Access -
Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes: a matching-adjusted indirect comparison of randomized trials
Clin Drug Investig. 2011;31(9):665-74. doi: 10.2165/11592490-000000000-00000.
2011Signorovitch J, Wu EQ, Swallow E, Kantor E, Fan L, Gruenberger J
HEOR, Epidemiology & Market Access
-
December 4, 2024
-
June 20, 2024
-
February 26, 2024
-
January 9, 2024
-
December 1, 2023
-
April 10, 2023
-
March 3, 2023
-
February 13, 2023
-
July 11, 2022
-
March 29, 2022